Adicet Bio (NASDAQ:ACET – Get Free Report) was downgraded by HC Wainwright from a “buy” rating to a “neutral” rating in a report issued on Wednesday, MarketBeat Ratings reports.
Several other equities research analysts have also recently commented on ACET. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Adicet Bio in a research report on Wednesday, August 14th. StockNews.com lowered Adicet Bio from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Wedbush reiterated an “outperform” rating and set a $5.00 price objective on shares of Adicet Bio in a report on Tuesday.
Get Our Latest Stock Analysis on Adicet Bio
Adicet Bio Price Performance
Adicet Bio (NASDAQ:ACET – Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.03. Equities analysts anticipate that Adicet Bio will post -1.35 EPS for the current year.
Hedge Funds Weigh In On Adicet Bio
A number of large investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in Adicet Bio during the first quarter worth about $28,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Adicet Bio during the 1st quarter worth approximately $37,000. American International Group Inc. boosted its holdings in shares of Adicet Bio by 74.2% in the 1st quarter. American International Group Inc. now owns 26,319 shares of the company’s stock valued at $62,000 after buying an additional 11,214 shares during the last quarter. Point72 DIFC Ltd boosted its holdings in shares of Adicet Bio by 77.5% in the 2nd quarter. Point72 DIFC Ltd now owns 33,441 shares of the company’s stock valued at $40,000 after buying an additional 14,596 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Adicet Bio in the second quarter valued at $43,000. 83.89% of the stock is currently owned by institutional investors and hedge funds.
About Adicet Bio
Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Further Reading
- Five stocks we like better than Adicet Bio
- How to buy stock: A step-by-step guide for beginners
- 3 Leveraged ETFs to Multiply Returns
- P/E Ratio Calculation: How to Assess Stocks
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- What is the NASDAQ Stock Exchange?
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.